摘要
幽门螺杆菌(Hp)是一级致癌因子,感染范围广、持续时间长,根治性差,临床获得的Hp毒力变异明显,感染后因患者炎性因子表达不一致,造成感染后临床表现和转归不同。因此对于细菌基因多态性和人炎性因子多态性之间的相互作用已成为今后治疗Hp感染的研究方向。
Helicobacter pylori（Hp） is considered as the type I carcinogen. The bacteria infection expands all over the world and lasts for a long time which means the treatment can not cure it completely. Because of the polymorphisms of the bacteria gene,clinical Hp has various significantly different toxic factors, which can cause the different outcomes, for the polymorphisms of infected persons＇ inflammation factor genes. The interaction between the bacterial gene polymorphism and human inflammatory factors has become the future direction of treatment of Hp infection.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2011年第19期1527-1530,共4页
Journal of Applied Clinical Pediatrics
基金
国家科技支撑计划项目(2007BAI04B02)
长江学者和创新团队发展计划资助(IRT0935)
关键词
幽门螺杆菌
基因多态性
炎性因子
helicobacter pylori
gene polymorphisms
inflammation factor
